Subject: Ragwitek PA Policy 1134-A 04-2022

Drug

RAGWITEK  (short ragweed pollen allergen extract)

Policy:

FDA-approved Indications
Ragwitek is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Ragwitek is approved for use in persons 5 through 65 years of age.

Ragwitek is not indicated for the immediate relief of allergic symptoms.

 
COVERAGE CRITERIA
The requested drug will be covered with prior authorization when the following criteria are met:
      •    The requested drug is being prescribed as immunotherapy for
            the treatment of short ragweed pollen-induced allergic rhinitis
      AND
      •     The diagnosis has been confirmed by positive skin test or in
             vitro testing for pollen-specific IgE antibodies for short
             ragweed pollen.
      AND
      •      The patient does not have any of the following: A) Severe,
              unstable or uncontrolled asthma, B) History of any severe
              systemic allergic reaction or any severe local reaction to
              sublingual allergen immunotherapy, C) History of eosinophilic
              esophagitis
      AND
      •      The requested drug is being prescribed by, or in consultation
              with, an allergist or immunologist

Place of Service:

Outpatient

The above policy is based on the following references:

1. Ragwitek [package insert]. Hørsholm, Denmark: ALK-Abelló A/S.; April 2021.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed March 14, 2022.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com. Accessed March 14, 2022.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

August 14, 2022